Skip to main content
HCPCS Q9967 · Level II · Part B drug

HCPCS Q9967: Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for Q9967

Billing unit
1 ML
Locm 300-399mg/ml iodine,1ml
ASP payment limit
$0.186
October 2026; +20.0% vs July 2026
Practitioner MUE
300
MAI 3
OPPS status
SI N
NCCI exposure
5 col-2 pairs
100% allow a modifier
Coverage articles
0
none list this code

TL;DR

HCPCS Q9967 is the Level II code for Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml, billed per 1 ML. The Medicare Part B ASP payment limit for October 2026 is $0.186 per billing unit, up 20.0% from July 2026. The practitioner MUE allows up to 300 units per date of service (MAI 3). Under OPPS it carries status indicator N. Diagnostic agents are usually packaged under OPPS (status N) in the hospital outpatient setting, so separate payment applies mainly in the physician office under Part B. The ASP crosswalk maps 95 NDCs to it, sold as Optiray 320, Ioversol Injection 678 MG/ML, Optiray 350 by Liebel-Flarsheim Company LLC, Bracco Diagnostics Inc., GE Healthcare Inc.. It is the bundled column-2 code in 5 NCCI pairs, most often with Q9958, Q9960, Q9961. No current Billing and Coding Article lists Q9967, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q9967 at $0.186 per 1 ML for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.155 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q9967
QuarterPayment limitPerCoinsurance
October 2026$0.1861 ML20%
July 2026$0.1551 ML—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 95 NDCs from 6 labelers to Q9967. Report the NDC in the claim's drug segment and bill the number of Q9967 units that equals the quantity administered divided by 1 ML; the last column gives units per full package.

NDCs that crosswalk to Q9967
NDCDrug nameLabelerPackage sizeBilling units / package
00019-1323-06Optiray 320Liebel-Flarsheim Company LLC50 × 251250
00019-1323-11Optiray 320Liebel-Flarsheim Company LLC100 × 121200
00019-1323-16Optiray 320Liebel-Flarsheim Company LLC150 × 121800
00019-1323-21Optiray 320Liebel-Flarsheim Company LLC200 × 122400
00019-1323-52Optiray 320Liebel-Flarsheim Company LLC50 × 201000
00019-1323-65Ioversol Injection 678 MG/MLLiebel-Flarsheim Company LLC500 × 63000
00019-1323-78Optiray 320Liebel-Flarsheim Company LLC50 × 201000
00019-1323-87Optiray 320Liebel-Flarsheim Company LLC125 × 202500
00019-1323-90Optiray 320Liebel-Flarsheim Company LLC100 × 202000
00019-1323-95Optiray 320Liebel-Flarsheim Company LLC75 × 201500
00019-1333-06Optiray 350Liebel-Flarsheim Company LLC50 × 251250
00019-1333-11Optiray 350Liebel-Flarsheim Company LLC100 × 121200
00019-1333-16Optiray 350Liebel-Flarsheim Company LLC150 × 121800
00019-1333-21Optiray 350Liebel-Flarsheim Company LLC200 × 122400
00019-1333-65Ioversol Injection 741 MG/MLLiebel-Flarsheim Company LLC500 × 63000
00019-1333-78Optiray 350Liebel-Flarsheim Company LLC50 × 201000
00019-1333-87Optiray 350Liebel-Flarsheim Company LLC125 × 202500
00019-1333-90Optiray 350Liebel-Flarsheim Company LLC100 × 202000
00019-1333-95Optiray 350Liebel-Flarsheim Company LLC75 × 201500
00270-1315-25Isovue-300Bracco Diagnostics Inc.30 × 10300
00270-1315-35Isovue-300Bracco Diagnostics Inc.100 × 101000
00270-1315-45Isovue-300Bracco Diagnostics Inc.200 × 102000
00270-1315-95Isovue-300Bracco Diagnostics Inc.500 × 63000
00270-1316-35Isovue-370Bracco Diagnostics Inc.100 × 101000
00270-1316-45Isovue-370Bracco Diagnostics Inc.200 × 102000
00270-1316-95Isovue-370Bracco Diagnostics Inc.500 × 63000
00270-1412-15Isovue-M-300Bracco Diagnostics Inc.15 × 10150
00270-7300-10IomeronBracco Diagnostics Inc.100 × 565600
00270-7300-20IomeronBracco Diagnostics Inc.200 × 102000
00407-1413-10Omnipaque 300GE Healthcare Inc.10 × 10100
00407-1413-48Omnipaque 300 (Novaplus)GE Healthcare Inc.500 × 105000
00407-1413-53Omnipaque 300GE Healthcare Inc.125 × 101250
00407-1413-59Omnipaque 300GE Healthcare Inc.30 × 10300
00407-1413-61Omnipaque 300GE Healthcare Inc.50 × 10500
00407-1413-62Omnipaque 300GE Healthcare Inc.75 × 10750
00407-1413-63Omnipaque 300GE Healthcare Inc.100 × 101000
00407-1413-65Omnipaque 300GE Healthcare Inc.150 × 101500
00407-1413-66Omnipaque 300GE Healthcare Inc.200 × 102000
00407-1413-68Omnipaque 300GE Healthcare Inc.500 × 105000
00407-1413-69Omnipaque 300GE Healthcare Inc.125 × 101250
00407-1413-72Omnipaque 300GE Healthcare Inc.500 × 105000
00407-1413-86Omnipaque 300GE Healthcare Inc.50 × 10500
00407-1413-87Omnipaque 300GE Healthcare Inc.100 × 101000
00407-1413-88Omnipaque 300GE Healthcare Inc.150 × 101500
00407-1413-89Omnipaque 300GE Healthcare Inc.500 × 105000
00407-1414-48Omnipaque 350 (Novaplus)GE Healthcare Inc.500 × 105000
00407-1414-72Omnipaque 350GE Healthcare Inc.500 × 105000
00407-1414-76Omnipaque 350GE Healthcare Inc.125 × 101250
00407-1414-82Omnipaque 350GE Healthcare Inc.50 × 10500
00407-1414-84Omnipaque 350GE Healthcare Inc.100 × 101000
00407-1414-85Omnipaque 350GE Healthcare Inc.125 × 101250
00407-1414-86Omnipaque 350GE Healthcare Inc.150 × 101500
00407-1414-87Omnipaque 350GE Healthcare Inc.200 × 102000
00407-1414-88Omnipaque 350GE Healthcare Inc.500 × 105000
00407-1414-89Omnipaque 350GE Healthcare Inc.50 × 10500
00407-1414-90Omnipaque 350GE Healthcare Inc.75 × 10750
00407-1414-91Omnipaque 350GE Healthcare Inc.100 × 101000
00407-1414-93Omnipaque 350GE Healthcare Inc.150 × 101500
00407-1414-94Omnipaque 350GE Healthcare Inc.200 × 102000
00407-1414-95Omnipaque 350GE Healthcare Inc.125 × 101250
Showing 60 of 95 NDCs.

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q9967. For practitioners the limit is 300 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q9967 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services3003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital3003 Date of Service Edit: ClinicalPrescribing Information

NCCI edits and add-on relationships

In the practitioner PTP file v323r0 (effective October 1, 2026), Q9967 is the column-2 code in 5 active pairs, 100% of which allow a modifier (indicator 1), and the column-1 code in 5. 0 historical pairs have been deleted over time. CMS's most frequent rationale: Mutually exclusive procedures.

When billed with these column-1 codes, Q9967 is the bundled component unless the pair allows a modifier and the documentation supports a distinct service.

Column-1 codes most often paired with Q9967
Column-1 codePairs
Q9958 Hocm <=149 mg/ml iodine, 1ml1
Q9960 Hocm 200-249mg/ml iodine,1ml1
Q9961 Hocm 250-299mg/ml iodine,1ml1
Q9962 Hocm 300-349mg/ml iodine,1ml1
Q9963 Hocm 350-399mg/ml iodine,1ml1

These codes are considered components of Q9967 when reported together on the same date of service.

Column-2 codes most often bundled into Q9967
Column-2 codePairs
Q9951 Locm >= 400 mg/ml iodine,1ml1
Q9959 Hocm 150-199mg/ml iodine,1ml1
Q9964 Hocm>= 400mg/ml iodine, 1ml1
Q9965 Locm 100-199mg/ml iodine,1ml1
Q9966 Locm 200-299mg/ml iodine,1ml1

Q9967 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q9967 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, Q9967 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Common denials for Q9967 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks Q9967 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS Q9967

What does HCPCS code Q9967 describe?

Q9967 is defined by CMS as "Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml". Each billing unit represents 1 ML, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for Q9967 in October 2026?

The ASP-based payment limit is $0.186 per 1 ML, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $0.155.

How many units of Q9967 can be billed per day?

The practitioner Medically Unlikely Edit is 300 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q9967?

The October 2026 ASP crosswalk lists 95 NDCs from 6 labelers: Optiray 320 (Liebel-Flarsheim Company LLC); Ioversol Injection 678 MG/ML (Liebel-Flarsheim Company LLC); Optiray 350 (Liebel-Flarsheim Company LLC); Ioversol Injection 741 MG/ML (Liebel-Flarsheim Company LLC). For example NDC 00019-1323-06 is a 50 package equal to 1250 billing units. The crosswalk's billing-units-per-package figure converts each package into Q9967 units.

Does Q9967 have NCCI bundling edits?

In the v323r0 practitioner PTP file, Q9967 appears as the column-2 (bundled) code in 5 active pairs and as the column-1 code in 5. 100% of the column-2 pairs allow a modifier (indicator 1). The most frequent column-1 partners are Q9958, Q9960, Q9961, Q9962, Q9963, and CMS's leading rationale is "Mutually exclusive procedures".

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.